20 / 32
How does ARCHER 1050 compare with other
1L trials of 2
nd
& 3
rd
Gen EGFR TKI
LUX-Lung 7
1
ARCHER 1050
2
FLAURA
3
Median OS
27.9 m v 24.5 m
34.1 m v 26.8 m
Immature
Phase
IIb (n=319)
III (n=452)
III (n=556)
Arms
Afatinib vs gefitinib
Dacomitinib vs gefitinib
Osimertinib vs gefitinib/erlotinib
RR
70% v 56%
75% v 71.2%
80% v 76%
PFS (all comers)
11 m v 10.9 m (BIRC)
HR 0.73 (0.57 – 0.95) p=0.017
14.7 m v 9.2 m (BIRC) [No BM]
HR 0.59 (0.47-0.74) p<0.0001
17.7 m v 9.7 m (BIRC)
HR 0.45 (0.36 – 0.57) p<0.001
PFS (no brain mets)
19.1 m v 10.9 m (INV)
HR 0.46 (0.36-0.59) p<0.001
Park TLO 2016; Mok ASCO 2018; Soria NEJM 2018